From: Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
Technique | Parameter | Overall survival | Disease-free survival | ||||
---|---|---|---|---|---|---|---|
 |  | HR | 95% CI | p | HR | 95% CI | p |
FISH | HER1 | Â | Â | Â | Â | Â | Â |
 |    Continuous 0.1 | 1.02 | 0.97–1.07 | 0.380 | 1.03 | 0.98–1.07 | 0.301 |
 |    Continuous 1.0 | 1.24 | 0.77–2.00 |  | 1.28 | 0.80–2.03 |  |
 | HER2 |  |  |  |  |  |  |
 |    Continuous 0.1 | 1.02 | 1.01–1.02 | 0.001 | 1.02 | 1.01–1.03 | <0.001 |
 |    Continuous 1.0 | 1.16 | 1.06–1.26 |  | 1.18 | 1.08–1.29 |  |
 |    Dichotomous (≤1.5 vs. ≥1.6) | 2.07 | 1.33–3.21 | 0.001 | 2.33 | 1.48–3.68 | <0.001 |
 | HER3 |  |  |  |  |  |  |
 |    Continuous 0.1 | 1.07 | 0.99–1.15 |  | 1.09 | 1.01–1.18 | 0.031 |
 |    Continuous 1.0 | 1.88 | 0.88–4.01 | 0.102 | 2.35 | 1.08–5.11 |  |
 | HER4 |  |  |  |  |  |  |
 |    Continuous 0.1 | 0.90 | 0.75–1.09 | 0.289 | 0.92 | 0.76–1.12 | 0.395 |
 |    Continuous 1.0 | 0.36 | 0.06–2.36 |  | 0.43 | 0.06–3.03 |  |
IHC | HER1 | 1.66 | 0.96–2.86 | 0.070 | 1.55 | 0.87–2.77 | 0.139 |
 | HER2 | 1.42 | 0.90–2.25 | 0.131 | 1.58 | 0.99–2.54 | 0.057 |
 | HER3 | 0.84 | 0.51–1.37 | 0.484 | 0.93 | 0.55–1.56 | 0.778 |
 | HER4 | 1.48 | 0.97–2.26 | 0.070 | 1.51 | 0.97–2.33 | 0.066 |
 | HER2 divided | 1.72 | 1.07–2.75 | 0.024 | 1.89 | 1.16–3.08 | 0.010 |
 | Ki-67 | 1.49 | 0.87–2.55 | 0.145 | 1.44 | 0.83–2.49 | 0.197 |
 | ER | 0.58 | 0.37–0.91 | 0.018 | 0.59 | 0.37–0.96 | 0.031 |
 | PR | 0.48 | 0.27–0.74 | 0.002 | 0.42 | 0.24–0.71 | 0.001 |
Histology | pT | 1.62 | 1.35–1.93 | <0.001 | 1.72 | 1.43–2.08 | <0.001 |
 | pN | 1.98 | 1.67–2.35 | <0.001 | 2.18 | 1.81–2.62 | <0.001 |
 | Grading | 2.10 | 1.54–2.87 | <0.001 | 2.18 | 1.56–3.05 | <0.001 |